


AMENDMENTS TO THE CLAIMS

1 (Previously Presented). A compound of the Formula I



Formula I

wherein:

R1 is NHR10,(substituted or unsubstituted C₁-C₆alkyl)NHR10 or (unsubstituted or substituted C₃-C₈ cycloalkyl)NHR10;

R10 is hydrogen, C₁-C₆alkyl, C₁-C₆alkyl(OH), C₁-C₆alkylidenyl(OH)R11, or an amino protecting group;

R11 is C₁-C₆alkyl, C₂-C₆alkenyl, C₁-C₆alkyl(O)C₁-C₆alkyl, C(O)O-C₁-C₆alkyl, aryl, or C₁-C₆alkylaryl;

R2 is hydrogen, C₁-C₆alkyl, aryl, or C₁-C₆alkylaryl;

R4 is hydrogen, C₁-C₆alkyl, aryl, C₁-C₆alkylaryl, or C₂-C₆alkenyl;

R5 is hydrogen, aryl, C₁-C₆alkylaryl, hydroxy, C₁-C₆alkoxy, unsubstituted or substituted C₁-C₆alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C₁-C₆alkyl, unsubstituted or substituted C₂-C₆alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C₃-C₈ cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C₁-C₆alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C₁-C₆alkyl)C₃-C₈cycloalkyl, or unsubstituted or substituted C₁-C₆alkylaryl;

Q is -S(O)₂- or -C(O)-;


m is a number selected from 1 or 2;

R3 is substituted C₁-C₆alkylaryl, substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl, substituted C₃-C₈ cycloalkyl, substituted (C₁-C₆ alkyl) C₃-C₈ cycloalkyl, or aryl substituted by at least one -SO₂CF₃ group; and R9 is hydrogen, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, C₃-

C₈cycloalkenyl, cyano, optionally substituted aryl, optionally substituted -O-aryl, optionally substituted -N-aryl, optionally substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C₁-C₆alkyl, or C₁-C₆alkylaryl, wherein K1 is halo or -CF₃, and K2 is hydrogen, halo or -CF₃ or K1 and K2 together form a methylenedioxy group; or

R3 is optionally substituted aryl, C₁-C₆alkylaryl, C₁-C₆alkyl(O)-C₁-C₆alkylaryl, C₃-C₈ cycloalkyl, (C₁-C₆ alkyl) C₃-C₈ cycloalkyl; and R9 is aryl substituted by at least one -SO₂CF₃ group, -O-aryl substituted by at least one -SO₂CF₃ group, -N-aryl substituted by at least one -SO₂CF₃ group, or -S-aryl substituted by at least one -SO₂CF₃ group; or a pharmaceutically acceptable salt thereof.

2 (Previously Presented). A compound according to claim 1 having Formula II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 1 or a pharmaceutically acceptable salt thereof.

3 (Previously Presented). A compound according to claim 2 wherein R3 is selected from substituted C₁-C₆alkylaryl, substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl, or substituted (C₁-C₆ alkyl) C₃-C₈ cycloalkyl; or a pharmaceutically acceptable salt or solvate thereof.

4 (Previously Presented). A compound according to claim 3 wherein the substituted C₁-C₆alkylaryl or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thiienyl, oxazolyl, isoxazolyl and indolyl which is substituted by from one to three groups independently selected from C₁-C₆ alkyl, -OC₁-C₆ alkyl, -OCF₃, amide, aryl, aryloxy, SO₂(C₁-C₆ alkyl), SO₂CF₃, NHamide, carboxamide, sulfonamide, NHsulfonamide, imide,

hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

5 (Previously Presented). A compound according to claim 2 wherein R3 is a substituted C₁-C₆ alkylaryl group or a substituted C₁-C₆alkyl(O)-C₁-C₆alkyl aryl group wherein:

the C₁-C₆alkyl moiety within the substituted C₁-C₆ alkylaryl group is methyl, ethyl or propyl;

the C₁-C₆alkyl(O)-C₁-C₆alkyl moiety within the substituted C₁-C₆alkyl(O)- C₁-C₆alkyl aryl group is a moiety of formula -CH₂OCH₂;

the substituted aryl moiety is 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,4,6-trifluorophenyl, 2,3,4-trifluorophenyl, 2,4,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,3,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2-chloro-4-fluorophenyl, 2-methylphenyl, 2,6-difluoro-3-methylphenyl, 3,6-difluoro-2-chlorophenyl, 2-fluoro-6-chlorophenyl, 2-fluoro-3-chlorophenyl, 2-fluoro-4-chlorophenyl, 2,6-difluoro-3-chlorophenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2-trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-fluoro-3-trifluoromethylphenyl, 2-fluoro-6-trifluoromethylphenyl, 2-chloro-3-trifluoromethylphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 2-trifluoromethoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 4-methanesulphonylphenyl, or 2-methyl thiazolyl;


or a pharmaceutically acceptable salt or solvate thereof.

6 (Previously Presented). A compound according to claim 2 wherein R1 is



or a pharmaceutically acceptable salt or solvate thereof.

7 (Previously Presented). A compound according to claim 2 wherein R1 is selected from $-\text{C}(\text{CH}_2\text{F})_2\text{NH}_2$, $-\text{C}(\text{CH}_2\text{F})(\text{CH}_2\text{CH}_2\text{F})\text{NH}_2$, $-\text{C}(\text{CF}_3)(\text{CH}_3)\text{NH}_2$, $-\text{C}(\text{CH}_2\text{CH}_2\text{F})_2\text{NH}_2$,



8 (Previously Presented). A compound according to claim 2 wherein R6 and R7 are each $\text{C}_1\text{-}\text{C}_3$ alkyl or form a five or six membered carbocyclic ring; or R6 and R7 are independently $\text{C}_1\text{-}\text{C}_6$ alkyl or $\text{C}_2\text{-}\text{C}_6$ alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R6 is hydrogen and R7 is $\text{C}_1\text{-}\text{C}_6$ alkyl, $\text{C}_2\text{-}\text{C}_6$ alkenyl which is substituted by one, two, or three halo atoms; or R6 and R7 together with the carbon atom to which they are attached may form a $\text{C}_3\text{-}\text{C}_8$ cycloalkyl group which is optionally partly unsaturated and which is substituted by one, two, or three halo atoms; or a pharmaceutically acceptable salt thereof.

9 (Previously Presented). A compound according to claim 1 wherein R4 is hydrogen or methyl, or a pharmaceutically acceptable salt or solvate thereof.

10 (Previously Presented). A compound according to claim 2 wherein R5 is hydrogen, $\text{C}_1\text{-}\text{C}_6$ alkyl, $\text{C}_1\text{-}\text{C}_6$ alkoxy, $\text{C}_1\text{-}\text{C}_6$ alkyl which is substituted by hydroxy or $\text{C}_1\text{-}\text{C}_6$ alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

11 (Previously Presented). A compound according to claim 10 wherein R5 is hydrogen, methyl, ethyl, propyl or n-propyl, or a pharmaceutically acceptable salt thereof.

12 (Previously Presented). A compound according to claim 2 wherein R8 is hydrogen, $\text{C}_1\text{-}\text{C}_6$ alkyl, $(\text{C}_1\text{-}\text{C}_6\text{alkyl})\text{C}_3\text{-}\text{C}_8$ cycloalkyl, benzyl, 1-phenylethyl, $\text{C}_1\text{-}\text{C}_6$ alkyl which is substituted by hydroxy, methoxy, CONH_2 , or $\text{CON}(\text{CH}_3)_2$, or $\text{C}_1\text{-}\text{C}_6$ alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

13 (Previously Presented). A compound according to claim 12 wherein R8 is C₁-C₆alkyl which is substituted by hydroxy or C₁-C₆alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.


14 (Previously Presented). A compound according to claim 2 wherein R9 is selected from the group consisting of unsubstituted or substituted thiienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thiienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH₂, furanyl, benzo thiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

15 (Previously Presented). A compound according to claim 14 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thiienyl, thiazolyl, pyridyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, oxazolyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl, 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.


16 (Previously Presented). A pharmaceutical formulation comprising one or more compounds according to claim 1 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable diluents or carriers therefor.

17 (Previously Presented). A pharmaceutical formulation according to claim 16 wherein the formulation further comprises one or more growth hormone secretagogue compounds and/or a bone-antiresorptive agent.

18 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising coupling a compound of Formula XI or XIb




with a compound of formula XIII




wherein R1, R2, R3, R4, R5, R6, R7, R8 , R9 and Q are as defined in claim 1.

19 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising deprotecting a compound of Formula



wherein R2, R3, R4, R5, R6, R7, R8 , R9, m and Q are as defined in claim 1, and PG is an amino protecting group.

20 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising coupling a compound of Formula



with a compound of formula XIV




XIV

wherein R1, R2, R3, R4, R5, R6, R7, R8 , R9 and Q are as defined in claim 1.

21-23(Canceled).

24 (Previously Presented). A compound having the formula



wherein:

X is O, Y is 4-Cl, Z is 2-F and R5 is Et;

or

X is O, Y is 4-Cl, Z is 3-F and R5 is Et;

or

X is O, Y is 4-Cl, Z is 4-F and R5 is Et;

or

X is O, Y is 4-Cl, Z is 2,3-F₂ and R5 is Et;

or

X is O, Y is 4-Cl, Z is 2,5-F₂ and R5 is Et;

or

X is CH₂, Y is 4-Cl, Z is 2,6-F₂ and R5 is Et;

or

X is O, Y is 4-Cl, Z is 2,6-F₂ and R5 is Et;

or

X is CH₂, Y is 4-Cl, Z is 3,5-F₂ and R5 is Et;

or

X is O, Y is 4-Cl, Z is 2,4,6-F₃ and R5 is Et;

or

X is O, Y is 4-Cl, Z is 2,3,5-F₃ and R5 is Et;

or

X is O, Y is 4-Cl, Z is 2,6-Cl₂ and R5 is Et;

or

X is O, Y is 4-Cl, Z is 2-F-6-Cl and R5 is Et;

or

X is O, Y is 4-Cl, Z is 2-Cl-3,6-F₂ and R5 is Et;

or

X is O, Y is 4-Cl, Z is 2-CN and R5 is Et;

or a pharmaceutically acceptable salt thereof.

25 (Previously Presented). 2-(R)-2-(2-Amino-2-methylpropionylamino)-3-(2,6-difluoro-3-methylphenyl)methoxy propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; or a pharmaceutically acceptable salt thereof.